



Application of Human Three-Dimensional Multicellular Models for Personalized Cancer Therapy

Guest Editor:

Dr. Barbara Mayer

Department of General, Visceral,
and Transplant Surgery, Ludwig-
Maximilians-University Munich,
H02-312, Marchioninistrasse 15,
81377 Munich, Germany

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

Personalized cancer therapy based on individual tumor characteristics is playing an increasingly important role in cancer treatment. Currently, personalized oncology is mainly defined as the molecular profiling of tumors to select a targeted therapy for the individual cancer patient. However, a significant number of cancer patients do not benefit from this treatment selection strategy. This highlights the need to consider additional tumor characteristics relevant to drug response and to incorporate additional testing systems beyond the evaluation of genetic information into the treatment decision process.

The Special Issue "Application of Three-Dimensional Human Multicellular Models for Personalized Cancer Therapy" aims to provide an update on complex 3D human cancer models such as organoids, spheroids, tissue cultures, on-a-chip platforms, bioprinted models, and microfluidic systems developed for drug selection for individual cancer patients.

Dr. Barbara Mayer
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)